Canagliflozin may not be good for the heart, FDA says
January 10th 2013Canagliflozin (Janssen Research & Development), developed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, raised the level of bad cholesterol in patients during clinical trials and may post heart risks, according to FDA and reported by Reuters.
Read More
Industry-sponsored studies report more favorable findings
January 2nd 2013Industry-sponsored studies are more likely to report favorable findings on the sponsor’s drug or device, according to a recent literature review. Healthcare professionals who rely on systematic reviews to aid decision-making should be aware of this industry influence on conclusions.
Read More
Antimicrobial stewardship programs-A review for the formulary decision-maker
December 31st 2012Antimicrobial stewardship programs are being implemented in a variety of settings to assist with the challenges associated with the management of infectious diseases. Here's a review of ASPs from the perspective of a formulary decision-maker.
Read More
Bariatric surgery can help, but not cure, diabetes
December 31st 2012Gastric bypass surgery can improve glycemic control in adults with type 2 diabetes, but doesn't cure diabetes, according to the largest community-based study of long-term diabetes outcomes after bariatric surgery, published online ahead of print in Obesity Surgery.
Read More
Recent FDA action (through December 2012) related to, Rabeprazole sodium delayed-release sprinkle capsules, CXA-201, CB-215, Buprenorphine subdermal implant, LX1033, ISIS-TTR Rx, Digoxin Immune Fab, Glucagon, AAV1-FS344, Trans sodium crocetinate, Betamethasone valerate foam 0.12%
Read More
African-Americans more likely to die at first coronary event
December 31st 2012African-American men and women continue to have higher risks of dying at the first presentation of heart disease compared with their white counterparts, according to a study published in the Journal of the American Medical Association.
Read More
FDA Actions in Brief December 2012
December 31st 2012Recent FDA Approvals (through December 2012) related to (Bedaquiline, Janssen, Oseltamivir, Genetech, Apixaban, Bristol-Myers Squibb, Lomitapide, Aegerion, Varicella zoster immune globulin preparation, Cangene, Teduglutide, NPS Pharmaceuticals, Pasireotide diaspartate, Novartis, Ponatinib, ARIAD Pharmaceuticals, Influenza virus vaccine, GlaxoSmithKline, Raxibacumab, Crofelemer, Salix, Cabozantinib, Exelixis)
Read More
NABP with state boards create action plan to help enforce compounding regulations
December 13th 2012Last week, NABP Executive Director Carmen Catizone, MS, RPh, unveiled an action plan to inspect nonresident compounding pharmacies and create a database to share regulatory information about these pharmacies with the state boards of pharmacy nationwide. This was in response to the fungal meningitis outbreak that took the lives of 37 individuals and injured 590.
Read More